BENEFIT OF ABIRATERONE ACETATE PLUS PREDNISONE (AA plus P) ADDED TO ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH HIGH-RISK, NEWLY DIAGNOSED METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

被引：0
|
作者：
Metin, H. [1 ]
McQuarrie, K. [2 ]
Thilakarathne, M. [3 ]
Diels, J. [3 ]
Ito, T. [4 ]
Li, T. [5 ]
Sulur, G. [6 ]
Chi, K. N. [7 ]
Fizazi, K. [8 ]
机构：
[1] Janssen Cilag GmbH, North Rhine Westphalia, Germany
[2] Janssen Res & Dev, Spring House, PA USA
[3] Janssen Cilag, Beerse, Belgium
[4] Janssen Cilag, High Wycombe, Bucks, England
[5] Janssen Global Serv, Raritan, NJ USA
[6] Janssen Res & Dev, Los Angeles, CA USA
[7] BC Canc Agcy, Vancouver Ctr, Vancouver, BC, Canada
[8] Univ Paris Sud, Gustave Roussy, Villejuif, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.317
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN171
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [1] Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
    Miller, Kurt
    AKTUELLE UROLOGIE, 2019, 50 (06) : 625 - 628
  • [2] Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC).
    Fizazi, Karim
    Larsen, Julie S.
    Matheny, Shannon
    Molina, Arturo
    Li, Jinhui
    Todd, Mary Beth
    Yu, Margaret K.
    Kheoh, Thian San
    Namphuong Tran
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)
    Woo, H.
    Fizaz, K.
    Sulur, G.
    Tran, N.
    Fein, L.
    Matsubara, N.
    Rodriguez-Antolin, A.
    Alekseev, B.
    Ozguroglu, M.
    Ye, D.
    Feyerabend, S.
    Protheroe, A.
    Li, S.
    Luna, Y.
    Mundle, S.
    Chi, K.
    BJU INTERNATIONAL, 2019, 123 : 27 - 28
  • [4] Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).
    Fizazi, Karim
    Namphuong Tran
    Fein, Luis Enrique
    Matsubara, Nobuaki
    Antolin, Alfredo Rodriguez
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    Sulur, Giri
    Luna, Yesenia
    Li, Susan
    Mundle, Suneel
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer
    Yanagisawa, Takafumi
    Kimura, Takahiro
    Mori, Keiichiro
    Suzuki, Hirotaka
    Sano, Takayuki
    Otsuka, Takashi
    Iwamoto, Yuya
    Fukuokaya, Wataru
    Miyajima, Keiichiro
    Enei, Yuki
    Sakanaka, Keigo
    Matsukawa, Akihiro
    Onuma, Hajime
    Obayashi, Koki
    Tsuzuki, Shunsuke
    Hata, Kenichi
    Shimomura, Tatsuya
    Miki, Jun
    Egawa, Shin
    PROSTATE, 2022, 82 (01): : 3 - 12
  • [6] LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC)
    Feyerabend, S.
    Tran, N.
    Fein, L.
    Matsubara, N.
    Rodriguez Antolin, A.
    Alekseev, B.
    Ozguroglu, M.
    Ye, D.
    Protheroe, A.
    De Porre, P.
    Kheoh, T.
    Park, Y. C.
    Todd, M.
    Chi, K.
    Fizazi, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 113 - 113
  • [7] Benefits of Abiraterone Acetate Plus Prednisone (AA plus P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO)
    Chi, K.
    Protheroe, A.
    Rodriguez Antolin, A.
    Facchini, G.
    Suttmann, H.
    Matsubara, N.
    Ye, Z-Q.
    Keam, B.
    Li, T.
    McQuarrie, K.
    Jia, B.
    De Porre, P.
    Martin, J.
    Todd, M. B.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer
    Gschwend, Juergen E
    Miller, Kurt
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (01): : 41 - 49
  • [9] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
    Fizazi, Karim
    Tran, Namphuong
    Fein, Luis Enrique
    Matsubara, Nobuaki
    Antolin, Alfredo Rodriguez
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary Beth
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer
    Sathianathen, Niranjan J.
    Oestreich, Makinna C.
    Brown, Sarah Jane
    Gupta, Shilpa
    Konety, Badrinath R.
    Dahm, Philipp
    Kunath, Frank
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
12345